Pub Date : 2023-10-17DOI: 10.1089/psymed.2023.0007
William Brennan, Alex R. Kelman, Alexander B. Belser
Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PIs) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators during all phases of treatment, sometimes called “psychological support,” “monitoring,” “psychedelic-assisted therapy,” or “psychedelic-assisted psychotherapy.” A brief review of recent research, historical studies, safety considerations, and participant perspectives suggests that PI has a substantive and critical impact on treatment outcomes. Methods: This systematic review examines the reporting practices on PI in published clinical trial results. The review employs a search of PubMed/Medline and PSYCinfo databases to identify relevant articles. It includes quantitative clinical studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) or empathogenic drugs (MDMA) since 2000. The analytic approach follows a modified version of assessment items based on CONSORT extension statement and TIDieR checklist. Results: Thirty-three published psychedelic clinical trials met criteria. The review reveals that many published reports on psychedelic clinical trials did not report basic aspects of the intervention: 33% did not report the number of sessions, 45% did not report the duration of sessions, 42% did not report provider credentials, 52% did not report whether their intervention used a therapy manual, 64% did not reference a manual that was available to readers, and 82% did not report that they assessed treatment fidelity. A comparison with non-psychedelic trials shows that psychedelic trial reports underreport on key items related to PI. Discussion: The study highlights the problems of underreporting and the importance of improving reporting practices regarding PI in psychedelic clinical trials to enhance research standardization and improve treatment outcomes. Recommendations for improving reporting practices are provided.
{"title":"A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions","authors":"William Brennan, Alex R. Kelman, Alexander B. Belser","doi":"10.1089/psymed.2023.0007","DOIUrl":"https://doi.org/10.1089/psymed.2023.0007","url":null,"abstract":"Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PIs) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators during all phases of treatment, sometimes called “psychological support,” “monitoring,” “psychedelic-assisted therapy,” or “psychedelic-assisted psychotherapy.” A brief review of recent research, historical studies, safety considerations, and participant perspectives suggests that PI has a substantive and critical impact on treatment outcomes. Methods: This systematic review examines the reporting practices on PI in published clinical trial results. The review employs a search of PubMed/Medline and PSYCinfo databases to identify relevant articles. It includes quantitative clinical studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) or empathogenic drugs (MDMA) since 2000. The analytic approach follows a modified version of assessment items based on CONSORT extension statement and TIDieR checklist. Results: Thirty-three published psychedelic clinical trials met criteria. The review reveals that many published reports on psychedelic clinical trials did not report basic aspects of the intervention: 33% did not report the number of sessions, 45% did not report the duration of sessions, 42% did not report provider credentials, 52% did not report whether their intervention used a therapy manual, 64% did not reference a manual that was available to readers, and 82% did not report that they assessed treatment fidelity. A comparison with non-psychedelic trials shows that psychedelic trial reports underreport on key items related to PI. Discussion: The study highlights the problems of underreporting and the importance of improving reporting practices regarding PI in psychedelic clinical trials to enhance research standardization and improve treatment outcomes. Recommendations for improving reporting practices are provided.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"127 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136034506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-16DOI: 10.1089/psymed.2023.0028
Alexander Wen, Nikhita Singhal, Brett D.M. Jones, Richard J. Zeifman, Shobha Mehta, Mohammad A. Shenasa, Daniel M. Blumberger, Zafiris J. Daskalakis, Cory R. Weissman
Introduction: Effective blinding is especially challenging in randomized controlled trials (RCTs) involving psychedelics due to the inherent alterations in consciousness that these compounds induce. In this systematic review and exploratory analysis, we aim at synthesizing the methodologies used in RCTs involving classic psychedelics and identify procedures that can help minimize unblinding and bias. Methods: We completed a literature search that included prospective RCTs published between 1963 and January 2023, in which participants were randomized to receive either a classic psychedelic or placebo. Results: A total of 1402 papers were included in the initial search. After eligibility criteria were applied, 50 papers from 48 clinical trials were included. Most studies were double blinded (n = 34), used a within-subjects design (n = 32 studies), and included inert placebos (n = 35). The majority of studies did not report on the integrity of blinding procedures (n = 34 studies); however, in studies that did, blinding was unsuccessful. Conclusion: To improve blinding and lower expectancy effects, we suggest incorporating active placebos and utilizing dose response or active comparator study designs.
{"title":"A Systematic Review of Study Design and Placebo Controls in Psychedelic Research","authors":"Alexander Wen, Nikhita Singhal, Brett D.M. Jones, Richard J. Zeifman, Shobha Mehta, Mohammad A. Shenasa, Daniel M. Blumberger, Zafiris J. Daskalakis, Cory R. Weissman","doi":"10.1089/psymed.2023.0028","DOIUrl":"https://doi.org/10.1089/psymed.2023.0028","url":null,"abstract":"Introduction: Effective blinding is especially challenging in randomized controlled trials (RCTs) involving psychedelics due to the inherent alterations in consciousness that these compounds induce. In this systematic review and exploratory analysis, we aim at synthesizing the methodologies used in RCTs involving classic psychedelics and identify procedures that can help minimize unblinding and bias. Methods: We completed a literature search that included prospective RCTs published between 1963 and January 2023, in which participants were randomized to receive either a classic psychedelic or placebo. Results: A total of 1402 papers were included in the initial search. After eligibility criteria were applied, 50 papers from 48 clinical trials were included. Most studies were double blinded (n = 34), used a within-subjects design (n = 32 studies), and included inert placebos (n = 35). The majority of studies did not report on the integrity of blinding procedures (n = 34 studies); however, in studies that did, blinding was unsuccessful. Conclusion: To improve blinding and lower expectancy effects, we suggest incorporating active placebos and utilizing dose response or active comparator study designs.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-19DOI: 10.1089/psymed.2023.0036
Brian S. Barnett, Miranda Arakelian, David Beebe, Jared Ontko, Connor Riegal, Willie O. Siu, Jeremy Weleff, Harrison G. Pope
Background: Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually identical methods, assessing whether American psychiatrists display greater optimism about the therapeutic use of hallucinogens in 2022–23. Methods: We e-mailed our survey instrument to 1,000 randomly selected American Psychiatric Association members—250 resident-fellows and 750 attending psychiatrists—in late 2022 and early 2023. We calculated descriptive statistics and used a non-parametric trend test to compare the current survey responses with those from 2016. We also constructed a multivariate logistic regression model to assess attributes of respondents that predicted moderate/strong agreement with plans to incorporate hallucinogen-assisted therapy into their own practice. Results: The response rate was 13.1% (N = 131). Respondents were demographically similar to the 2016 respondents. A majority moderately/strongly believed that hallucinogens show promise in treating psychiatric conditions (80.9%) and substance use disorders (SUDs) (60.8%). Large majorities also moderately/strongly supported research into hallucinogens' therapeutic potential for psychiatric conditions (93.9%) and SUDs (88.6%), as well as federal funding of associated clinical trials (84.7% and 80.9%, respectively). Comparisons to 2016 showed significantly increased optimism regarding the therapeutic promise of hallucinogens and decreased concern about risks, with 50.4% of respondents reporting moderate/strong intentions to incorporate hallucinogen-assisted therapy into their practice. Conclusions: Our data reveal a striking positive shift in attitudes toward the therapeutic potential of hallucinogens among American psychiatrists since 2016, with a majority of responding psychiatrists planning to incorporate hallucinogen-assisted therapy into their practice if regulatory approval is granted.
{"title":"American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey","authors":"Brian S. Barnett, Miranda Arakelian, David Beebe, Jared Ontko, Connor Riegal, Willie O. Siu, Jeremy Weleff, Harrison G. Pope","doi":"10.1089/psymed.2023.0036","DOIUrl":"https://doi.org/10.1089/psymed.2023.0036","url":null,"abstract":"Background: Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually identical methods, assessing whether American psychiatrists display greater optimism about the therapeutic use of hallucinogens in 2022–23. Methods: We e-mailed our survey instrument to 1,000 randomly selected American Psychiatric Association members—250 resident-fellows and 750 attending psychiatrists—in late 2022 and early 2023. We calculated descriptive statistics and used a non-parametric trend test to compare the current survey responses with those from 2016. We also constructed a multivariate logistic regression model to assess attributes of respondents that predicted moderate/strong agreement with plans to incorporate hallucinogen-assisted therapy into their own practice. Results: The response rate was 13.1% (N = 131). Respondents were demographically similar to the 2016 respondents. A majority moderately/strongly believed that hallucinogens show promise in treating psychiatric conditions (80.9%) and substance use disorders (SUDs) (60.8%). Large majorities also moderately/strongly supported research into hallucinogens' therapeutic potential for psychiatric conditions (93.9%) and SUDs (88.6%), as well as federal funding of associated clinical trials (84.7% and 80.9%, respectively). Comparisons to 2016 showed significantly increased optimism regarding the therapeutic promise of hallucinogens and decreased concern about risks, with 50.4% of respondents reporting moderate/strong intentions to incorporate hallucinogen-assisted therapy into their practice. Conclusions: Our data reveal a striking positive shift in attitudes toward the therapeutic potential of hallucinogens among American psychiatrists since 2016, with a majority of responding psychiatrists planning to incorporate hallucinogen-assisted therapy into their practice if regulatory approval is granted.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135010784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-06DOI: 10.1089/psymed.2023.0018
M. Weintraub, Jessica K. Jeffrey, Charles S. Grob, Megan C. Ichinose, R. L. Bergman, Ziva D. Cooper, D. Miklowitz
{"title":"Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development","authors":"M. Weintraub, Jessica K. Jeffrey, Charles S. Grob, Megan C. Ichinose, R. L. Bergman, Ziva D. Cooper, D. Miklowitz","doi":"10.1089/psymed.2023.0018","DOIUrl":"https://doi.org/10.1089/psymed.2023.0018","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75381245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01Epub Date: 2023-09-13DOI: 10.1089/psymed.2022.0009
Megan Miller, William E Rosa, Alden Doerner Rinaldi, Katie Addicott, Dingle Spence, Yvan Beaussant
Background: Psychedelic-assisted therapy (PAT) has re-emerged as a promising intervention for addressing mental health conditions and existential concerns. Despite growing enthusiasm, PAT may be difficult to integrate into mainstream health systems. The rich sacramental traditions of psychedelics, their centering of the human experience, proposed substrates of action, context-dependent outcomes, and highly relational method of therapy all challenge dominant reductionistic approaches of the biomedical model. Hospice and palliative care are well established as holistic evidence-based standards of care, yet they began as a radical grassroots movement. Hospice and palliative care models may offer unique insights to support the growing field of PAT.
Purpose: The intention of this commentary is to articulate the deep synergies between hospice and palliative care and PAT, with the intention of fostering interdisciplinary dialogue that may aid in implementation of human-centered high-quality PAT.
Conclusions: Various aspects of hospice and palliative care models were identified and explored, which may support the implementation of human-centered high-quality PAT at scale. These include a focus on truly interdisciplinary care, applying a holistic lens to health and illness, bearing witness to suffering and healing, customized care, centering human relationships, decentralized models of care, generalist/specialist competencies, fostering spirituality, organizing as a social moment around shared goals, and growth from grassroots community organizations to mature care systems. Although hospice and palliative care can offer practical lessons for scaling human-centered experiential therapies, PAT, with its radical centering of meaning-making and relationship in the healing process, may also mutually innovate the fields of hospice and palliative care.
{"title":"Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy.","authors":"Megan Miller, William E Rosa, Alden Doerner Rinaldi, Katie Addicott, Dingle Spence, Yvan Beaussant","doi":"10.1089/psymed.2022.0009","DOIUrl":"10.1089/psymed.2022.0009","url":null,"abstract":"<p><strong>Background: </strong>Psychedelic-assisted therapy (PAT) has re-emerged as a promising intervention for addressing mental health conditions and existential concerns. Despite growing enthusiasm, PAT may be difficult to integrate into mainstream health systems. The rich sacramental traditions of psychedelics, their centering of the human experience, proposed substrates of action, context-dependent outcomes, and highly relational method of therapy all challenge dominant reductionistic approaches of the biomedical model. Hospice and palliative care are well established as holistic evidence-based standards of care, yet they began as a radical grassroots movement. Hospice and palliative care models may offer unique insights to support the growing field of PAT.</p><p><strong>Purpose: </strong>The intention of this commentary is to articulate the deep synergies between hospice and palliative care and PAT, with the intention of fostering interdisciplinary dialogue that may aid in implementation of human-centered high-quality PAT.</p><p><strong>Conclusions: </strong>Various aspects of hospice and palliative care models were identified and explored, which may support the implementation of human-centered high-quality PAT at scale. These include a focus on truly interdisciplinary care, applying a holistic lens to health and illness, bearing witness to suffering and healing, customized care, centering human relationships, decentralized models of care, generalist/specialist competencies, fostering spirituality, organizing as a social moment around shared goals, and growth from grassroots community organizations to mature care systems. Although hospice and palliative care can offer practical lessons for scaling human-centered experiential therapies, PAT, with its radical centering of meaning-making and relationship in the healing process, may also mutually innovate the fields of hospice and palliative care.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"1 3","pages":"124-129"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41159598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1089/psymed.2023.29002.psh
Peter S. Hendricks, Charles D. Nichols
Psychedelic MedicineVol. 1, No. 3 EditorialFree AccessThe Elephant in the Room: Personal Use of Psychedelics Among Psychedelic ResearchersPeter S. Hendricks and Charles D. NicholsPeter S. Hendricks*Address correspondence to: Peter S. Hendricks, PhD, Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, 530 Beacon Parkway West, Suite 702, Birmingham, AL 35209, USA, E-mail Address: [email protected]Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.Search for more papers by this author and Charles D. NicholsDepartment of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29002.pshAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In this issue, Pagán et al.1 report that among US medical students, personal use of psychedelics was associated with more positive attitudes toward psilocybin. More positive attitudes toward psilocybin were, in turn, associated with greater willingness to recommend psilocybin-assisted psychotherapy, if FDA approved. Herrmann et al.2 also found that psychiatric medication prescribers attributed improvements in depression, anxiety, and well-being to personal use of psychedelics. These two studies comport with a prior study in Psychedelic Medicine by Aday et al.,3 which found that almost 90% of the therapists associated with Usona Institute's Phase II clinical trial of psilocybin for major depressive disorder reported personal use of psychedelics. Collectively, this raises important questions around personal use of psychedelics among those conducting research (and in the anticipated future, clinical interventions) with these compounds.One question is whether personal use of psychedelics might play a role in the training of clinical research staff. This is not a novel idea. In 1957, when psychedelics were still thought of as psychotomimetics, the psychedelic pioneer Humphry Osmond wrote, “There is one golden rule that should be applied in working with model psychoses. One should start with oneself. Unless this is done, one cannot expect to make sense of someone else's communications and, consequently, the value of the work is greatly reduced.”4 Osmond's perspective was shared by other luminaries in the field including Albert Hofmann5 and Timothy Leary, Ralph Metzner, and Richard Alpert,6 and appears to have resonated with the scientific community. Indeed, personal use of psychedelics among psychedelic researchers in the 1950s through the early 1970s may have been commonplace, and it has been promoted by contemporary researchers with similar rationale.7And yet, whether personal use of psychedelics
叙事身份，理性，和微剂量经典迷幻药。国际麻醉品杂志2019;70:33-39。Crossref, Medline, Google Scholar12。傅芳，Nowak MA, Christakis NA，等。同质性的进化科学通报2012;2:845。Crossref, Medline, Google Scholar13。McPherson M, Smith-Lovin L, Cook JM。同类之鸟:社交网络中的同质性。社会科学学报2001;27:415-444。Crossref, Google Scholar14。与人口统计学上相似的客户一起工作的治疗师的伦理考虑。中国科学学报(英文版);2016;26:678-687。Crossref, Google Scholar15。史蒂文斯j风暴天堂:LSD和美国梦。大西洋月刊出版社:美国纽约;1987. Google ScholarFiguresReferencesRelatedDetails第1卷第3期2023年9月信息版权所有2023,Mary Ann Liebert, Inc，出版商本文引用:Peter S. Hendricks和Charles D. Nichols。房间里的大象:致幻剂研究人员的个人使用。迷幻药。2023.09月122-123.http://doi.org/10.1089/psymed.2023.29002.pshPublished vol: 1 Issue 3: 2023.09月13日pdf下载
{"title":"The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers","authors":"Peter S. Hendricks, Charles D. Nichols","doi":"10.1089/psymed.2023.29002.psh","DOIUrl":"https://doi.org/10.1089/psymed.2023.29002.psh","url":null,"abstract":"Psychedelic MedicineVol. 1, No. 3 EditorialFree AccessThe Elephant in the Room: Personal Use of Psychedelics Among Psychedelic ResearchersPeter S. Hendricks and Charles D. NicholsPeter S. Hendricks*Address correspondence to: Peter S. Hendricks, PhD, Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, 530 Beacon Parkway West, Suite 702, Birmingham, AL 35209, USA, E-mail Address: [email protected]Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.Search for more papers by this author and Charles D. NicholsDepartment of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29002.pshAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In this issue, Pagán et al.1 report that among US medical students, personal use of psychedelics was associated with more positive attitudes toward psilocybin. More positive attitudes toward psilocybin were, in turn, associated with greater willingness to recommend psilocybin-assisted psychotherapy, if FDA approved. Herrmann et al.2 also found that psychiatric medication prescribers attributed improvements in depression, anxiety, and well-being to personal use of psychedelics. These two studies comport with a prior study in Psychedelic Medicine by Aday et al.,3 which found that almost 90% of the therapists associated with Usona Institute's Phase II clinical trial of psilocybin for major depressive disorder reported personal use of psychedelics. Collectively, this raises important questions around personal use of psychedelics among those conducting research (and in the anticipated future, clinical interventions) with these compounds.One question is whether personal use of psychedelics might play a role in the training of clinical research staff. This is not a novel idea. In 1957, when psychedelics were still thought of as psychotomimetics, the psychedelic pioneer Humphry Osmond wrote, “There is one golden rule that should be applied in working with model psychoses. One should start with oneself. Unless this is done, one cannot expect to make sense of someone else's communications and, consequently, the value of the work is greatly reduced.”4 Osmond's perspective was shared by other luminaries in the field including Albert Hofmann5 and Timothy Leary, Ralph Metzner, and Richard Alpert,6 and appears to have resonated with the scientific community. Indeed, personal use of psychedelics among psychedelic researchers in the 1950s through the early 1970s may have been commonplace, and it has been promoted by contemporary researchers with similar rationale.7And yet, whether personal use of psychedelics","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135349542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1089/psymed.2023.29001.rfs2022
Jamie Peters
Psychedelic MedicineVol. 1, No. 3 AnnouncementFree AccessRosalind Franklin Society Proudly Announces the 2022 Award Recipient for Psychedelic MedicineJamie PetersJamie PetersDepartment of Anesthesiology University of Colorado, Anschutz Medical Campus, Aurora, CO, USASearch for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29001.rfs2022AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail The Rosalind Franklin Society (RFS), in partnership with Mary Ann Liebert, Inc., publishers, enthusiastically congratulate our distinguished recipient of the 2022 annualRFS Award in Sciencefor this journal, which recognizes the outstanding research and published work of women and underrepresented minority scientists, physicians, and engineers.Jasper A. Heinsbrock, Giuseppe Gianotti, Joel Banilla, David E. Olson, and Jamie Peters. “Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.” (June 2023): http://doi.org//10.1089/psymed.2023.0009AbstractThe potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed tabernanthalog (TBG), a novel 5-HT2A agonist with reduced hallucinogenic potential. We previously demonstrated that TBG has therapeutic efficacy in a preclinical model of opioid use disorder in rats and separately in a binge model of alcohol drinking in mice. Alcohol is commonly co-used with opioids, yet preclinical models that recapitulate this comorbidity are lacking. We thus employed a polydrug model of heroin and alcohol co-use to screen the therapeutic efficacy of TBG on behavioral metrics of addiction. Whereas pre-exposure to alcohol in the home cage did not impact single-substance self-administration or relapse rates in this model, rats were subsequently allowed to co-self-administer heroin and alcohol. This allowed us to test the effects of TBG on motivation for each substance, measured as break points in a progressive ratio test, where the amount of effort required to obtain a single reward increases exponentially with each earned reward. TBG effectively reduced motivation for heroin and alcohol in this test, indicating its efficacy is preserved in animals with a history of heroin and alcohol polydrug use.BiosketchDr. Jamie Peters is an associate professor of anesthesiology at the University of Colorado Anschutz Medical Campus. Her research focuses on the neural circuits controlling drug-seeking behaviors, including circuits that promote addiction pathology, as well as those that limit it. Her work led to the identification of a neural circuit that functions as a limiter of drug seeking in preclinical rodent models of addiction. Dr. Peters has been searching for a common limiter circuit capable of diminishing a broad spectrum of addictive behavior
迷幻MedicineVol。1、第3号公告免费访问罗莎琳德·富兰克林协会自豪地宣布2022年迷幻药物奖获得者杰米·彼得斯杰米·彼得斯麻醉系科罗拉多大学安舒茨医学院，科罗拉多州奥罗拉美国搜索本文作者的更多论文发表在线:2023年9月13日https://doi.org/10.1089/psymed.2023.29001.rfs2022AboutSectionsPDF/EPUB权限和引文下载引文链接添加到收藏夹返回出版分享分享在facebook上推特链接在redditemail罗莎琳德·富兰克林协会(RFS)，与玛丽·安·利伯特公司合作，出版商，热烈祝贺我们的杰出收件人获得2022年度RFS科学奖。该奖项旨在表彰女性和未被充分代表的少数族裔科学家、医生和工程师的杰出研究和出版工作。Jasper A. Heinsbrock, Giuseppe Gianotti, Joel Banilla, David E. Olson和Jamie Peters。“在多种药物使用模型中，Tabernanthalog降低了海洛因和酒精的动机。(2023年6月):http://doi.org//10.1089/psymed.2023.0009AbstractThe由于致幻剂的特性，致幻剂作为神经精神疾病治疗药物的潜在用途受到限制。为了克服这一限制，我们开发了tabernanthalog (TBG)，一种新型的5-HT2A激动剂，具有降低致幻剂的潜力。我们之前证明了TBG在大鼠阿片类药物使用障碍的临床前模型和小鼠酗酒模型中具有治疗效果。酒精通常与阿片类药物共同使用，但缺乏概括这种共病的临床前模型。因此，我们采用海洛因和酒精共同使用的多药模型来筛选TBG对成瘾行为指标的治疗效果。然而，在这个模型中，在家庭笼子中预先暴露于酒精并不影响单一物质的自我给药或复发率，随后允许大鼠共同自我给药海洛因和酒精。这让我们能够测试TBG对每种物质动机的影响，并以渐进比率测试中的断点来衡量，即获得单一奖励所需的努力量会随着获得的奖励呈指数增长。在这项试验中，TBG有效地降低了海洛因和酒精的动机，这表明它的功效在有海洛因和酒精多重药物使用史的动物中保持不变。杰米·彼得斯是科罗拉多大学安舒茨医学院的麻醉学副教授。她的研究重点是控制药物寻求行为的神经回路，包括促进成瘾病理的回路，以及那些限制成瘾的回路。她的工作导致了在临床前啮齿动物成瘾模型中作为药物寻找限制器的神经回路的识别。彼得斯博士一直在寻找一种能够减少各种成瘾行为的共同限制电路。在David Olson博士的团队发表的一篇开创性的《自然》(Nature)论文中(2021年)，Peters博士展示了一种类似致幻剂的化合物tabernanthalog(一种伊博加因的合成衍生物)对大鼠海洛因复发的持久治疗效果。她也是《迷幻医学》的编委会成员。数据参考资料相关信息第1卷第3期2023年9月信息版权所有2023,Mary Ann Liebert, Inc，出版商本文引用:Jamie Peters。罗莎琳德·富兰克林协会自豪地宣布2022年迷幻药奖获得者。迷幻药。2023年9月121-121.http://doi.org/10.1089/psymed.2023.29001.rfs2022Published卷:1期:2023年9月13日在线提前打印:2023年8月14日pdf下载
{"title":"Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for <i>Psychedelic Medicine</i>","authors":"Jamie Peters","doi":"10.1089/psymed.2023.29001.rfs2022","DOIUrl":"https://doi.org/10.1089/psymed.2023.29001.rfs2022","url":null,"abstract":"Psychedelic MedicineVol. 1, No. 3 AnnouncementFree AccessRosalind Franklin Society Proudly Announces the 2022 Award Recipient for Psychedelic MedicineJamie PetersJamie PetersDepartment of Anesthesiology University of Colorado, Anschutz Medical Campus, Aurora, CO, USASearch for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29001.rfs2022AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail The Rosalind Franklin Society (RFS), in partnership with Mary Ann Liebert, Inc., publishers, enthusiastically congratulate our distinguished recipient of the 2022 annualRFS Award in Sciencefor this journal, which recognizes the outstanding research and published work of women and underrepresented minority scientists, physicians, and engineers.Jasper A. Heinsbrock, Giuseppe Gianotti, Joel Banilla, David E. Olson, and Jamie Peters. “Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.” (June 2023): http://doi.org//10.1089/psymed.2023.0009AbstractThe potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed tabernanthalog (TBG), a novel 5-HT2A agonist with reduced hallucinogenic potential. We previously demonstrated that TBG has therapeutic efficacy in a preclinical model of opioid use disorder in rats and separately in a binge model of alcohol drinking in mice. Alcohol is commonly co-used with opioids, yet preclinical models that recapitulate this comorbidity are lacking. We thus employed a polydrug model of heroin and alcohol co-use to screen the therapeutic efficacy of TBG on behavioral metrics of addiction. Whereas pre-exposure to alcohol in the home cage did not impact single-substance self-administration or relapse rates in this model, rats were subsequently allowed to co-self-administer heroin and alcohol. This allowed us to test the effects of TBG on motivation for each substance, measured as break points in a progressive ratio test, where the amount of effort required to obtain a single reward increases exponentially with each earned reward. TBG effectively reduced motivation for heroin and alcohol in this test, indicating its efficacy is preserved in animals with a history of heroin and alcohol polydrug use.BiosketchDr. Jamie Peters is an associate professor of anesthesiology at the University of Colorado Anschutz Medical Campus. Her research focuses on the neural circuits controlling drug-seeking behaviors, including circuits that promote addiction pathology, as well as those that limit it. Her work led to the identification of a neural circuit that functions as a limiter of drug seeking in preclinical rodent models of addiction. Dr. Peters has been searching for a common limiter circuit capable of diminishing a broad spectrum of addictive behavior","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135349543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-28DOI: 10.1089/psymed.2023.0017
Andrew D. Penn, R. Yehuda
{"title":"Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda","authors":"Andrew D. Penn, R. Yehuda","doi":"10.1089/psymed.2023.0017","DOIUrl":"https://doi.org/10.1089/psymed.2023.0017","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76247073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-18DOI: 10.1089/psymed.2023.0022
Antonio F. Pagán, C. Lex, J. Soares, T. Meyer
{"title":"Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?","authors":"Antonio F. Pagán, C. Lex, J. Soares, T. Meyer","doi":"10.1089/psymed.2023.0022","DOIUrl":"https://doi.org/10.1089/psymed.2023.0022","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73178383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-18DOI: 10.1089/psymed.2023.0020
Philip Kamilar-Britt, E. Gordis, M. Earleywine
{"title":"The Therapeutic Alliance in Psychedelic-Assisted Psychotherapy: A Novel Target for Research and Interventions","authors":"Philip Kamilar-Britt, E. Gordis, M. Earleywine","doi":"10.1089/psymed.2023.0020","DOIUrl":"https://doi.org/10.1089/psymed.2023.0020","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"258 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75765591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：